Personalis Receives Medicare Coverage for NeXT Personal in Lung Cancer Surveillance
The NeXT Personal molecular residual disease test can now be used for surveillance of patients with Stage I to III non-small cell lung cancer.
Latest Articles
Editor's Top Picks
What Clinical Lab Leaders Predict for 2026
AI, new diagnostics, and shifting care delivery models are among the clinical laboratory predictions for 2026.
Be the First to Know What’s Next in the Lab
Every week, we dig into the biggest shifts, breakthroughs, and tech transforming clinical diagnostics. Straightforward, insightful, and always relevant.Critical Resources
Diagnostic Innovations
Cirena Launches Long RNA Synthesis Platform for CRISPR Applications
The technology is designed to deliver high-purity long RNA to support CRISPR and functional genomics workflows.
Equipment & Supply Spotlight
Cenevo Launches Two AI Agents to Automate Lab Workflows
Cenevo has launched two AI agents for lab workflow automation, aiming to cut manual work and implementation costs by up to 50%, according to the company. The agents support protocol digitization and no-code workflow generation.
News, Know-How & Standards
Disease Detection & Understanding
FDA Approves PD-L1 Test to Guide Immunotherapy in Ovarian and Related Cancers
PD-L1 testing is now cleared to help identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for anti–PD-1 therapy.
